Embed

Academic

Authors

Bernard Escudier

Bernard Escudier,Institut Gustave Roussy,Oncology,Urology,Pharmacology

Edit

Bernard Escudier

Institut Gustave Roussy

Publications: 264 | Citations: 4412

Fields: Oncology, Urology, Pharmacology

Collaborated with 976 co-authors from 1990 to 2011 | Cited by 10823 authors

Cumulative Annual

Sort by:

Publications (264)

BibTeX | RIS | RefWorks Download

Sequential use of targeted agents in the treatment of renal cell carcinoma (Citations: 5)

, , , , ,

Journal: Critical Reviews in Oncology Hematology - CRIT REV ONCOL HEMATOL , vol. 77, no. 1, pp. 48-62, 2011

Transcription Factor E3 and Transcription Factor EB Renal Cell Carcinomas: Clinical Features, Biological Behavior and Prognostic Factors (Citations: 3)

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=49103033&selfId1=23614293&selfId2=0&maxNumber=12&query=

Journal: Journal of Urology - J UROL , vol. 185, no. 1, pp. 24-29, 2011

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=56631860&selfId1=23614293&selfId2=0&maxNumber=12&query=

Journal: Nature , vol. 480, no. 7375, pp. 94-98, 2011

Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=59318633&selfId1=23614293&selfId2=0&maxNumber=12&query=

Journal: Journal of Medical Genetics - J MED GENET , vol. 48, no. 4, pp. 226-234, 2011

Renal Cell Carcinoma (RCC) in Patients With End-Stage Renal Disease Exhibits Many Favourable Clinical, Pathologic, and Outcome Features Compared With RCC in the General Population

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=49320619&selfId1=23614293&selfId2=0&maxNumber=12&query=

Journal: European Urology - EUR UROL , vol. 60, no. 2, pp. 366-373, 2011

Sort by:

Citations (4412 times by 2858 publications)

Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=57404882&selfId1=23614293&selfId2=0&maxNumber=12&query=

Journal: PLOS One , vol. 7, no. 5, 2012

Identification of a 4microRNA Signature for Clear Cell Renal Cell Carcinoma Metastasis and Prognosis

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=57404627&selfId1=23614293&selfId2=0&maxNumber=12&query=

Journal: PLOS One , vol. 7, no. 5, 2012

Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines

, , , , , , , , , , ,

Journal: Oncogene , vol. 31, no. 13, pp. 1683-1694, 2012

Proton-Assisted Amino Acid Transporter PAT1 Complexes with Rag GTPases and Activates TORC1 on Late Endosomal and Lysosomal Membranes

, , , , , ,

Journal: PLOS One , vol. 7, no. 5, 2012

A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study

, , , , , , , , ,

Journal: Prostate Cancer and Prostatic Diseases - PROSTATE CANCER PROSTATIC DIS , vol. 15, no. 1, pp. 87-92, 2012

Comments

Co-authors (976)

Journals (71)

Keywords (329)

Bernard Escudier,Institut Gustave Roussy,Oncology,Urology,Pharmacology

Publications (264)

BibTeX | RIS | RefWorks Download

Sequential use of targeted agents in the treatment of renal cell carcinoma (Citations: 5)

Transcription Factor E3 and Transcription Factor EB Renal Cell Carcinomas: Clinical Features, Biological Behavior and Prognostic Factors (Citations: 3)

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma

Renal Cell Carcinoma (RCC) in Patients With End-Stage Renal Disease Exhibits Many Favourable Clinical, Pathologic, and Outcome Features Compared With RCC in the General Population

Citations (4412 times by 2858 publications)

Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas

Identification of a 4microRNA Signature for Clear Cell Renal Cell Carcinoma Metastasis and Prognosis

Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines

Proton-Assisted Amino Acid Transporter PAT1 Complexes with Rag GTPases and Activates TORC1 on Late Endosomal and Lysosomal Membranes

A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study


	View FAQ about top research areas and Fields of study

Bernard Escudier,Institut Gustave Roussy,Oncology,Urology,Pharmacology

Publications (264) BibTeX | RIS | RefWorks Download

Sequential use of targeted agents in the treatment of renal cell carcinoma (Citations: 5)

Transcription Factor E3 and Transcription Factor EB Renal Cell Carcinomas: Clinical Features, Biological Behavior and Prognostic Factors (Citations: 3)

Publications (264)

BibTeX | RIS | RefWorks Download